Journal article
Stem Cells, Cell Therapies and Bioengineering in Lung Biology and Diseases 2023
American journal of physiology. Lung cellular and molecular physiology, Vol.327(3), pp.L327-L340
05/21/2024
DOI: 10.1152/ajplung.00052.2024
PMCID: PMC11442098
PMID: 38772903
Abstract
Repair and regeneration of a diseased lung using stem cells or bioengineered tissues is an exciting therapeutic approach for a variety of lung diseases and critical illnesses. Over the past decade increasing evidence from preclinical models suggests that cells, which are not normally resident in the lung can be utilized to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating the use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those involving stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in our understanding of the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise during lung development and participate in normal and pathologic remodeling after lung injury. For the 2023 Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference, scientific symposia were chosen to reflect the most cutting-edge advances in these fields. Sessions focused on the integration of "-omics" technologies with function, the influence of immune cells on regeneration, and the role of the extracellular matrix in regeneration. The necessity for basic science studies to enhance fundamental understanding of lung regeneration and to design innovative translational studies was reinforced throughout the conference.
Details
- Title: Subtitle
- Stem Cells, Cell Therapies and Bioengineering in Lung Biology and Diseases 2023
- Creators
- Robert E Hynds - University College LondonChelsea M Magin - University of Colorado Anschutz Medical CampusLaertis Ikonomou - University at Buffalo, State University of New YorkYael Aschner - University of Colorado Anschutz Medical CampusMichael F Beers - University of PennsylvaniaJanette K Burgess - University Medical Center GroningenRebecca L Heise - Virginia Commonwealth UniversityPatrick S Hume - National Jewish HealthAnna D Krasnodembskaya - Queen's University BelfastShirley H J Mei - Ottawa HospitalAlexander V Misharin - Northwestern UniversityJin-Ah Park - Harvard UniversitySusan D Reynolds - Nationwide Children's HospitalDaniel J Tschumperlin - Mayo Clinic in FloridaAlicia E Tanneberger - University of Colorado Anschutz Medical CampusSriram Vaidyanathan - Nationwide Children's HospitalChristopher M Waters - University of KentuckyPatricia J Zettler - The Ohio State UniversityDaniel J Weiss - University of VermontAmy L Ryan - University of Iowa
- Resource Type
- Journal article
- Publication Details
- American journal of physiology. Lung cellular and molecular physiology, Vol.327(3), pp.L327-L340
- DOI
- 10.1152/ajplung.00052.2024
- PMID
- 38772903
- PMCID
- PMC11442098
- NLM abbreviation
- Am J Physiol Lung Cell Mol Physiol
- ISSN
- 1040-0605
- eISSN
- 1522-1504
- Publisher
- AMER PHYSIOLOGICAL SOC
- Grant note
- 1029996 / Pulmonary Fibrosis Foundation (PFF) N/A / Roche Holding | Genentech (Genentech USA) N/A / United Therapeutics Corporation (United Therapeutics) N/A / International Society for Cell Therapy N/A / Company of Biologists R13HL170688 / HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) N/A / Cystic Fibrosis Foundation (CFF) 2327935 / National Science Foundation (NSF)
- Language
- English
- Electronic publication date
- 05/21/2024
- Academic Unit
- Anatomy and Cell Biology
- Record Identifier
- 9984633260302771
Metrics
5 Record Views